CEO Markus Rohrwild and CDMO Thomas Langenickel provide an update on the company's peptide based drug development side, as well as venture and CRO arms.

Co-Founder & CEO David West describes the deal and why Proscia believes Agilent can take the business to a new level, and discusses how AI is changing pathology.

He comments on Arcus, Vaxcyte, Cytokinetics, BridgeBio, Maze Therapeutics, and Century Therapeutics. Chapters General sentiment - 1:37 Arcus - 3:49 Vaxcyte - 6:40 Cytokinetics - 10:30 BridgeBio - 14:48 Maze Therapeutics - 17:40 Century Therapeutics - 19:47

He goes over data presented at ASCO and discusses the company's pivotal trial, which is up and running and will read out in 2028. Plus, expansion into lung cancer in combination with a PD-1.

She says that consensus is a hazard ratio of 0.6 and that degrees of success could be viewed whether the data comes in lower or higher than that.

He describes how the company has transformed from being a gene therapy company focused on cardiology to having a broader approach to treating the root of disease.

CEO Gerri Henwood, who has successfully led numerous biotech companies, describes what about this opportunity excited her, and what is needed to get the program into the clinic.

Interviewed by Sisterhood Editorial Board Member Erika Smith, Paula Soteropoulos describes her experiences working for companies across a variety of modalities. Plus, she highlights the new women's health book she and her daughter co-authored: Restoring Balance. Biographies Ms. Soteropoulos has more than 35 years of biopharma industry experience in strategic and operational leadership areas including drug development, global commercialization, manufacturing, new company forma

He describes working on biotech companies (Cell Genesis and Millennium) in the early days of the biotech sector before it was common, the founding of Third Rock Ventures, and the unique culture at Third Rock that has produced so many investors and company builders who have achieved great things in their careers. Chapters Intro - 1:17 Education - 4:36 Early days at MGH - 9:32 Cell Genesys - 13:01 Millennium - 22:54 Founding Third Rock - 37:09 Culture - 47:25 Personal life - 1:

CEO John Baker describes how the project, done in collaboration with Ultima Genomics and Waters Corporation, will give researcher a tool to better understand the immune system. He also describes how IMU's blood sample based system works, and how it has been used for things such as to better understand which patients will respond to cancer immunotherapies.

CEO Jeff Glazier describes the backstory of how this treatment, which centers on melphalan, came about years ago, and is now in a clinical trial. He also discusses early clinical data that was presented at ESMO last year. Coverage brought to you by

Co-Founder & CEO Alison Liddy describes Relevium's program, which is designed to be an extended release prodrug. The initial clinical indication will be osteoarthritis of the knee. Coverage brought to you by

CEO Mark Gaffney walks us through the idea of targeting a DAMP and, in this case, S100A4 specifically, and describes the differentiated profile Calluna hopes to see compared to currently marketed therapies for IPF. Coverage brought to you by

Founder Fong Cho describes the unmet need, and the benefits of using the company's model and shuttle. She believes that NeuroSkye's peptide approach to its shuttle makes it an ideal platform to work together with a wide spectrum of therapeutic modalities. Coverage brought to you by

Founder Ben Pope describes the rationale of hitting the target and why he believes a clinical trial in Fragile X could provide evidence of the target's relevance in obesity, Alzheimer's, and more. Coverage brought to you by

Co-Founder & CEO Richard Novak describes the screening process and the benefits of focusing on existing compounds for which the profile is already largely known. The lead program is already in the clinic for Rett syndrome and Pitt Hopkins syndrome. Coverage brought to you by

Founder & CEO Shariq Usmani describes the solid tumor problem that traditional T-cell engagers have faced and explains how Hiba's are designed to cleave only in the tumor microenvironment. Coverage brought to you by

CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.

They discuss recent advances, what's ahead, Cigall's work in epigenetics, and how a new hospital will be purpose built for patients with the best new technologies in clinical research. Chapters Cancer research advances - 1:14 Cigall's work in epigenetics - 4:33 Dana-Farber's future new hospital - 9:29 AI centered approaches - 14:15 Looking ahead - 16:51

From the company's headquarters in Indianapolis, he describes where he thinks the obesity field could be headed in the next few years, what might be next after beta-amyloid in Alzheimer's, and how he plans to invest for the future.